Report Library
All Reports
Datamonitor Accountable Care Organizations - What Impact on Pharma
February 29, 2016
Datamonitor's independent research and analysis
provides extensive coverage of major disease areas, companies and strategic issues,
giving you the perspective to identify opportunities and threats arising from shifting market dynamics and the insights to
respond with faster, more effective decision-making. This strategy report focuses Accountable Care Organizations and what impact they
will
have on pharma including an evaluation of ACOs' structures, sizes, cultures, and risks.
Highlights
For more information on Datamonitor strategy reports, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
Highlights
- Maturing and multiplying ACOs matter to pharma.
- ACOs vary in structure, size, culture, and risk.
- There are still several uncertainties around the regulatory pathway in the US.
- Winners and losers in a shifting, consolidating provider landscape.
- Physician-led ACOs considered best for care, with health plan support.
- Medication management is not a priority for most ACOs.
- Commercial ACOs’ focus on short-term savings means drug cost caps.
- Pharma can help ACOs in other ways: data, education, and patient support.
For more information on Datamonitor strategy reports, please email BioMedTracker or call BioMedTracker Client Services at (858) 200-2357.
For our disclosures, please read the BioMedTracker Research Standards.
| Disease Group Covered: |
Allergy
Autoimmune/immunology Cardiovascular Dermatology Endocrine ENT/Dental Gastroenterology (Non Inflammatory Bowel Disease) Hematology Infectious Disease Metabolic Neurology Not Specified Obstetrics/Gynecology Oncology Ophthalmology Orthopedics Psychiatry Renal Respiratory Rheumatology (Non Autoimmune) Urology |
Additional Resources: